Viewing data from:

SULFASALAZINE

ANDA

SULFASALAZINE | A040349 | NUVO PHAMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: AZULFIDINE(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Sulfasalazine (2023)

Total Spending

$13.7M

Total Claims

468,253

Beneficiaries

112,219

Avg Cost/Unit

$0.14

Spending Trend

$14.1M(2019)→$15.6M(2020)→$14.6M(2021)→$15.1M(2022)→$13.7M(2023)

YoY Change:-8.6%

5yr CAGR:-4.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain2 active DMFs6 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

CAMBREX CHARLES CITY INCSULFASALAZINE USP

DMF 22391974

VALENS MOLECULES PRIVATE LTDSULFASALAZINE USP

DMF 261272012

ACF CHEMIEFARMA NVInactiveSULFASALAZINE

DMF 64891986

IFP INCInactiveSULFASALAZINE STARCH POWDER

DMF 71271987

CORDEN PHARMA BERGAMO SPAInactiveSULFASALAZINE

DMF 111631994

SALSBURY CHEMICALS INCInactiveSULFASALAZINE PVP

DMF 146882000

ZHEJIANG JIUZHOU PHARMACEUTICAL CO LTDInactiveSULFASALAZINE

DMF 147242000

SHANGHAI ZHONGXI SUNVE PHARMACEUTICAL CO LTDInactiveSULFASALAZINE

DMF 222382008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 500MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jan 11, 2002

No patent or exclusivity listings for this strength.